DDInter542 DDInter119
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Dicoumarol {u} (Compound) resembles {v} (Compound) Phenprocoumon
Dicoumarol {u} (Compound) binds {v} (Gene) CYP2C9
Dicoumarol {u} (Compound) downregulates {v} (Gene) P4HTM
Dicoumarol (Compound) resembles Phenprocoumon (Compound)
Dicoumarol (Compound) binds CYP2C9 (Gene)
Dicoumarol (Compound) downregulates P4HTM (Gene)